Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Natco PharmaNSE:NATCOPHARM -0.79%88 Altman Z2-Score is 8.15 as of Jul. 15, 2026, which is 20% below its 10-year median of 10.21. GuruFocus rates NSE:NATCOPHARM with a GF Score™ of 88/100 and a GF Value™ of ₹930.69 (Fairly Valued). The stock has 2 warning signs investors should review. Among 996 Drug Manufacturers companies, Natco Pharma ranks better than 79.22% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
Natco Pharma has a Altman Z2-Score of 8.15, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Natco Pharma's Altman Z2-Score or its related term are showing as below:
NSE:NATCOPHARM'
s Altman Z2-Score Range Over the Past 10 Years
Min: 7.05 Med: 10.21 Max: 15.29
Current: 8.15
During the past 13 years, Natco Pharma's highest Altman Z2-Score was 15.29. The lowest was 7.05. And the median was 10.21.
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
Altman Z2-Score does not apply to financial companies.
Natco Pharma Altman Z2-Score Related Terms
Natco Pharma Altman Z2-Score Historical Data
* Premium members only.
The historical data trend for Natco Pharma's Altman Z2-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NATCOPHARM vs ZTS, UTHR: Altman Z2-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Natco Pharma's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natco Pharma Altman Z2-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Natco Pharma's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Natco Pharma's Altman Z2-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
Natco Pharma's Altman Z2-Score for today is calculated with this formula:
Z
=
6.56
*
X1
+
3.26
*
X2
+
6.72
*
X3
+
1.05
*
X4_2
=
6.56
*
0.3045
+
3.26
*
0
+
6.72
*
0.1379
+
1.05
*
4.9774
=
8.15
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Natco Pharma (NSE:NATCOPHARM) has a Altman Z2-Score of 8.15 as of Jul. 15, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Natco Pharma and its competitors. This is 20% below median its historical median of 10.21. Over the past decade, Natco Pharma's Altman Z2-Score has ranged from 7.05 to 15.29. According to the industry distribution chart, Natco Pharma ranks #207 out of 996 companies in the Drug Manufacturers industry, placing it in the top 20.8%.
Is Natco Pharma's Altman Z2-Score too high?
Natco Pharma's current Altman Z2-Score of 8.15 is 20% below median its 10-year median of 10.21. Over the past 10 years, this metric has ranged from a low of 7.05 to a high of 15.29. The Drug Manufacturers industry median Altman Z2-Score is 3.88. Natco Pharma's value of 8.15 is 110.1% above this industry median. Based on the distribution chart, Natco Pharma ranks #207 out of 996 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Natco Pharma has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Natco Pharma's Altman Z2-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Natco Pharma ranks #207 out of 996 companies for Altman Z2-Score. This places Natco Pharma in the top 21% of its industry — outperforming the majority of peers. The industry median Altman Z2-Score is 3.88. Natco Pharma's value of 8.15 is 110.1% above this benchmark. Historically, Natco Pharma's own Altman Z2-Score has ranged from 7.05 to 15.29 over the past decade. While the company's 10-year median is 10.21 vs. the industry median of 3.88, Natco Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Drug Manufacturers company?
The median Altman Z2-Score among Drug Manufacturers companies is 3.88, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Natco Pharma's current Altman Z2-Score of 8.15 is 110.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Natco Pharma and its competitors. For the Drug Manufacturers industry, the median Altman Z2-Score is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Natco Pharma's current Altman Z2-Score is 8.15, which is 20% below median its own 10-year median of 10.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natco Pharma stock overvalued right now?
Based on GuruFocus' analysis, Natco Pharma (NSE:NATCOPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹930.69, compared to a current price of ₹972.25 — trading 4.5% above its estimated fair value. The current Altman Z2-Score is 8.15, which is 20% below median its 10-year median of 10.21 and 110.1% above the Drug Manufacturers industry median of 3.88. Natco Pharma's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Natco Pharma (NSE:NATCOPHARM), the current Altman Z2-Score is 8.15 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Natco Pharma (NSE:NATCOPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Natco Pharma stock appears to be overvalued.
The current stock price of ₹972.25 is trading 4.5% above its estimated GF Value™ of ₹930.69.
GuruFocus considers Natco Pharma to be Fairly Valued.
Key valuation signals for NSE:NATCOPHARM:
Altman Z2-Score: 8.15 (20% below median its 10-year median of 10.21)
GF Value™: ₹930.69 vs. price of ₹972.25 (4.5% above fair value)
Industry Position: 110.1% above the Drug Manufacturers median (#207 of 996)
No single metric tells the full story. See the NSE:NATCOPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
88GF Score
Get the complete analysis for NSE:NATCOPHARM
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NATCOPHARM has been successfully added to your 
